Precision BioSciences (DTIL) Expected to Announce Earnings on Thursday

Precision BioSciences (NASDAQ:DTIL) will likely be releasing its Q2 2025 earnings data before the market opens on Thursday, August 7th. Analysts expect Precision BioSciences to post earnings of ($0.09) per share and revenue of $6.27 million for the quarter.

Precision BioSciences (NASDAQ:DTIL) last posted its quarterly earnings data on Thursday, May 15th. The company reported ($2.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($1.78). The firm had revenue of $0.03 million during the quarter, compared to analysts’ expectations of $5.00 million. Precision BioSciences had a negative net margin of 42.99% and a negative return on equity of 69.26%. On average, analysts expect Precision BioSciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Precision BioSciences Price Performance

DTIL stock opened at $4.80 on Thursday. The company has a current ratio of 6.62, a quick ratio of 6.62 and a debt-to-equity ratio of 0.45. The company has a market capitalization of $53.23 million, a PE ratio of -2.39 and a beta of 1.43. Precision BioSciences has a 12-month low of $3.61 and a 12-month high of $11.09. The business’s fifty day moving average price is $4.75 and its 200 day moving average price is $4.95.

Insider Activity

In other Precision BioSciences news, CFO John Alexander Kelly sold 14,827 shares of the company’s stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.26, for a total transaction of $63,163.02. Following the sale, the chief financial officer owned 73,485 shares in the company, valued at $313,046.10. This represents a 16.79% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Corporate insiders own 4.50% of the company’s stock.

Analyst Ratings Changes

Separately, HC Wainwright reiterated a “buy” rating and issued a $60.00 price objective on shares of Precision BioSciences in a report on Wednesday, May 21st.

Precision BioSciences Company Profile

Precision BioSciences, Inc, an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA.